Intellia Therapeutics, Inc. (NTLA) incurred third-quarter 2024 loss of $1.34 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.37. In the year-ago quarter, Intellia had incurred a loss of $1.38 per share.The company’s total revenues currently comprise only collaboration revenues. Intellia reported revenues of $9.1 million for the third quarter of 2024 compared with $12 million reported in the year-ago quarter. Revenues however beat the Zacks Consensus Estimate of $8 million.The ...